Study Details

Back to Search Results

A Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT00924989

Astellas Study ID

The unique identification code given by the study sponsor.

OSI-906-301

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2009-012820-97

Follow Trial

Condition

Adrenal Cancer

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Dec 2009 - Oct 2012

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

139

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

University of Michigan

Ann Arbor, United States, 48109-2200

PMH - Princess Margaret Hospital

Toronto, Canada, M5G 2M9

Ohio State University

Columbus, United States, 43202

Universitaets Klinikum Wuerzburg

Wuerzburg, Germany, 97080

St Bartholomew's Hospital

London, United Kingdom, EC1A 7BE

University of Southern California

Los Angeles, United States, 90033

Dana-Farber Cancer Institute

Boston, United States, 02115

Beatson Oncology Centre

Glasgow, United Kingdom, G12 OYN

Centre hospitalier de l'Université de Montréal (CHUM)

Montreal, Canada, H2W 1T8

Royal North Shore Hospital Department of Endocrinology

St Leonards, Australia, 2065

Hôpital Cochin-Saint Vincent de Paul

Paris, France, 75679 Cedex 14

Centre Léon Bérard

Lyon, France, 69008

Duke Clinical Cancer Trials Services

Durham, United States, 27710

Universita di Torino

Orbassano, Italy, 10043

St. Joseph's Hospital

Hamilton, Canada, L8N 4A6

LMU München

Munich, Germany, 80336

Academic Medical Center

Amsterdam, Netherlands, 1105 AZ

Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie Oddzial w Gliwicach

Gliwice, Poland, 44-101

TGen Clinical Research Service at Scottsdale Healthcare

Scottsdale, United States, 85258

Yale Cancer Center

New Haven, United States, 06520-8062

Mary Crowley Cancer Research Center

Dallas, United States, 75230

University of Colorado Denver Cancer Center

Aurora, United States, 80045

Royal Marsden NHS Trust

London, United Kingdom, SW3 6JJ

Royal Adelaide Hospital Cancer Centre

Adelaide, Australia, 5000

Institut Paoli-Calmettes

Marseille, France, 13273 cedex 09

UCLA

Los Angeles, United States, 90095

Maxima Medisch Centrum (MMC)

Eindhoven, Netherlands, 5631 BM

OHSU Knight Cancer Institute

Portland, United States, 97239

CHU Bordeaux - Hôpital Haut-Lévêque

Pessac, France, 33604 CEDEX

Institut Gustave Roussy

Villejuif, France, 94805 cedex

Dartmouth Medical School

Lebanon, United States, 03756

CHRU Lille, Clinique Endocrinologique Marc Linquette

Lille, France, 59037 cedex

University Hospital Birmingham

Birmingham, United Kingdom, B15 2TH

Karmanos Cancer Institute

Detroit, United States, 48201

Charite Universitaetsmedizin

Berlin, Germany, 10117

Erasmus MC Rotterdam

Rotterdam, Netherlands, 3015 CE

Leiden University Medical Center

Leiden, Netherlands, 2333 ZA

University of Padua

Padova, Italy, 35128

University of Miami

Miami, United States, 33136

St. James' University hospital

Leeds, United Kingdom, LS9 7TF

MD Anderson Cancer Center

Houston, United States, 77030

Vanderbilt University Medical Center

Nashville, United States, 37232-6307

Università Cattolica del Sacro Cuore

Rome, Italy, 00168

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo